Gpb Scientific Announces Additional Growth Financing To Support Commercialization Of Curate™ Cell Processing System For Next-Generation Cell &Amp; Gene Therapies
Gpb Scientific Announces Additional Growth Financing To Support Commercialization Of Curate™ Cell Processing System For Next-Generation Cell &Amp; Gene Therapies
05/27/21, 12:07 PM
Location
carlsbadGPB Scientific, Inc., a developer of transformative cell processing technology for next generation cell and gene therapies, today announced raising an additional $18 million in capital as part of a previously announced financing, including commitments from existing investors Vensana Capital and Amgen Ventures, and from a new undisclosed healthcare investor. This financing will support expanded placements of GPB’s CurateTM Cell Processing System into partner facilities to enable optimized development and manufacturing in CAR-T and TCR programs, as well as development of the platform’s utility in additional types of cell and gene therapy applications.
Company Info
Location
carlsbad, new mexico, united states
Additional Info
GPB Scientific is a pioneering biomedical company realizing the promise of its Curate Cell Processing System. The Curate solution applies Deterministic Cell Separation (DCS™) technology, through a benchtop system and single-use cartridges that are currently optimized for T-cells. Designed with both manufacturing and clinical potential at the forefront, Curate™ delivers the scale and performance required to advance CAR-T and TCR applications beyond their limitations today. GPB works with leading biopharma and biotech companies, cancer centers, research institutes, and universities to advance the technology within and beyond this space, with future releases targeting additional cell types, use cases, disease states, and workflow paradigms.